Nirmatrelvir/ritonavir in heart transplant recipients with COVID-19: A case report on pharmaceutical care and drug interaction management
During the treatment process, managing complex polypharmacy posed significant challenges. Clinical pharmacists implemented individualized therapeutic drug monitoring to optimize antiviral efficacy. Through rational and effective pharmaceutical care, the clinical cure rate for HT recipients infected with COVID-19 was improved.
Authors
- Yue Wei (ORCID: https://orcid.org/0000-0002-4329-1261)
- Xiongjie Yu
- Jing Zhang (ORCID: https://orcid.org/0000-0002-3750-374X)
- Jun Su (ORCID: https://orcid.org/0000-0002-9349-8199)
- Jinhua Chen
- Lu Xu (ORCID: https://orcid.org/0009-0003-4772-9608)
Institutions
- Wuhan University (CN)
- Wuhan Asia Heart Hospital (CN)
- East China Normal University (CN)
Publication Details
- Journal
- Medicine
- Published
- 2025-06-27
- DOI
- https://doi.org/10.1097/md.0000000000043122
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00